Cardiology News / Recent Literature Review

Authors

  • Sofia Metaxa Evagelismos Hospital, Athens
  • Spyridon Koulouris Evagelismos Hospital, Athens
  • Antonis S Manolis Athens University School of Medicine & First Department of Cardiology, Evagelismos General Hospital of Athens, Athens, Greece

Keywords:

electrophysiology, cardiac pacing, news

Abstract

The ESC Annual Congress is slated for 27-31/8/2011 in Paris

 The TCT Annual Conference will be held in San Francisco 7-11/11/2011

 The AHA Annual Scientific Sessions are scheduled for 12-16/11/2011 in Orlando

 The Athens Cardiology Update 2012 is slated for April 5-7, 2012

 Reverse remodeling in cardiac resynchronization therapy reduces the risk of ventricular tachyarrhythmias in the MADIT-CRT trial

 The risk for ventricular tachyarrhythmias (VTA) (including ventricular tachycardia, ventricular fibrillation and ventricular flutter) was assessed in patients receiving cardiac resynchronization defribrillator therapy (CRT-D) or cardioverter-defribillator therapy (ICD) according to echocardiographic findings during 1-year follow-up. It was found that high responders to CRT-D (defined as ≥ 25% reduction in left ventricular end-systolic volume) experience a significant 55% reduction in the risk of VTA compared with ICD only patients (p<0.001), whereas the risk of VTA was not significantly different between low responders and ICD-only patients (p=0.21). (Barsheshet A et al, J Am Coll Cardiol 2011; 57: 2416-2423)

 High-dose atorvastatin does not prevent development of atrial fibrillation in patients with prior stroke or transient ischemic attack in the SPARCL trial

Statins are included as upstream therapy for prevention of new-onset of atrial fibrillation (AF) in the 2010 guidelines for the management of AF. The SPARCL trial tested the hypothesis that long-term treatment with high-dose atorvastatin (80 mg) reduces the occurrence of AF in 4731 patients with prior stroke or transient ischemic attack who were followed up for a median of 4.8 years (patients with prior paroxysmal AF were excluded from the trial). It was concluded that the time from randomization to first occurrence of new AF did not differ between atorvastatin (139 cases of new AF) and placebo (122 cases) group (hazard ratio 1.15, 95% CI 0.90-1.46, P=0.26). (Schwartz GG et al, Am Heart J  2011; 161: 993-999)... (excerpt)

Downloads

Published

2011-07-01

Issue

Section

Cardiology News